Based on the above analysis, we selected three molecular markers (CCDC170, COL14A1, THBS2) that are expected to be used in clinical ovarian cancer and verified them by Western blotting and immunofluorescence experiments. This evidence concerns the gene THBS2 and ovarian carcinoma.